ICER

ICER mulls GSK COPD drugs ahead of next Medicare negotiation
Pharmaphorum
Thu, 09/19/24 - 09:21 am
GSK
COPD
ICER
drug pricing
Medicare
Pfizer's ATTR heart disease drug needs hefty discount, says ICER draft report. What about Alnylam's Amvuttra?
Fierce Pharma
Fri, 07/19/24 - 11:36 am
Pfizer
tafamidis
ATTR-CM
ICER
drug pricing
ICER Finds ‘Substantial Uncertainties’ in Lykos’ MDMA Trials Ahead of Adcomm
BioSpace
Thu, 05/16/24 - 11:33 am
Lykos Therapeutics
ICER
PTSD
MDMA
As ICER places a spotlight on pharma's price hikes, J&J, Roche and more hit back
Fierce Pharma
Mon, 12/11/23 - 10:48 pm
ICER
JNJ
Roche
drug pricing
U.S. watchdog lifts price estimate for Bluebird, Vertex/CRISPR gene therapies to $2.1 million
Reuters
Fri, 07/14/23 - 10:07 am
ICER
gene therapy
Vertex Pharmaceuticals
CRISPR Therapeutics
Bluebird Bio
drug pricing
sickle cell disease
Vertex/CRISPR's gene editing therapy cost effective at $1.9 million - pricing review group
Yahoo/Reuters
Thu, 04/13/23 - 10:01 am
Vertex Pharmaceutials
CRISPR Therapeutics
gene therapy
sickle cell disease
ICER
ICER dials up recommended price range for Eisai's Leqembi—but still calls for sizable discount
Fierce Pharma
Wed, 03/1/23 - 06:55 pm
ICER
Eisai
Leqembi
drug pricing
Alzheimer's disease
Eisai and Biogen’s latest Alzheimer’s drug needs to be cheaper than the last one, analysts say
Stat
Thu, 12/22/22 - 11:10 am
Biogen
Eisai
Alzheimer's disease
drug pricing
ICER
lecanemab
Aligning drug prices with ICER estimates could save tens of billions of dollars — JAMA paper
Endpoints
Wed, 12/14/22 - 07:35 pm
ICER
Inflation Reduction Act
drug pricing
On its annual list of price hike offenders, ICER calls out Bausch's Xifaxan, J&J's Invega
Fierce Pharma
Wed, 12/7/22 - 10:10 am
ICER
drug pricing
Bausch Health
Xifaxan
JNJ
Invega
Cost watchdog ICER backs multimillion-dollar price tags for BioMarin, CSL hemophilia gene therapies
Fierce Pharma
Thu, 11/3/22 - 11:02 am
ICER
drug pricing
gene therapy
Biomarin
CSL
Bluebird Bio
hemophilia
ICER on MS drugs: TG's ublituximab not cost effective at the same price as Roche's ocrelizimab
Endpoints
Tue, 10/18/22 - 10:36 am
ICER
MS
multiple sclerosis
drug pricing
ublituximab
TG Therapeutics
ICER Deems Hemophilia Gene Therapies Worth the $2.5M Price Tag
BioSpace
Thu, 09/15/22 - 10:14 am
hemophilia
gene therapy
ICER
Biomarin
Chugai
Roche
CSL Behring
Vivus’ Qsymia beats out weight loss competitors in pricing watchdog's latest cost-effectiveness analysis
Endpoints
Wed, 07/13/22 - 08:22 pm
Vivus
Qsymia
weight loss
ICER
Novo Nordisk
Saxenda
Wegovy
Even at $2M+, ICER calls bluebird's potential gene therapy for blood disorder 'superior' to standard of care
Endpoints
Thu, 06/2/22 - 10:22 am
Bluebird Bio
ICER
gene therapy
FDA
beti-cel
ICER says Pfizer's Paxlovid, Merck's molnupiravir both cost effective, but their benefits are far from equal
Fierce Pharma
Tue, 05/10/22 - 10:50 am
ICER
Pfizer
Paxlovid
Merck
Ridgeback Biotherapeutics
molnupiravir
COVID-19
ICER says bluebird bio’s $2.1m gene therapy is cost-effective
Pharmaforum
Thu, 04/14/22 - 10:36 am
Bluebird Bio
ICER
beti-cel
FDA
A rarity for ICER: Cost watchdog says Covid-19 therapeutics appropriately priced in the US
Endpoints
Thu, 02/3/22 - 11:09 am
ICER
drug pricing
COVID-19
FDA delays its decision on Bristol Myers' $13B heart drug another three months
Endpoints
Fri, 12/17/21 - 11:18 am
Bristol Myers Squibb
mavacamten
ICER
FDA
FDA delays its decision on Bristol Myers' $13B heart drug another three months
Endpoints
Fri, 11/19/21 - 11:08 am
Bristol Myers Squibb
FDA
ICER
mavacamten
obstructive hypertrophic cardiomyopathy

Pages